A Quicky Review of CIRM Finances; More Scrutiny of Stem Cell Agency Promised in February
Strategy, vision, 'other fun things' on table next month
The $12 billion California stem cell and gene research program received a quick financial once-over last week with the promise of more to come in February by the only entity charged with evaluating the agency’s fiscal performance.
The 47-minute review came Dec. 28 in the midst of the holiday season. No action was taken by the state’s
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.